Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension

Código QR

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension

Kenji Inoue1, Minako Shiokawa1, Michitaka Sugahara1, Risako Higa1, Masato Wakakura1, Goji Tomita21Inouye Eye Hospital, Tokyo, Japan; 2Second Department of Ophthalmology, Toho University School of Medicine, Tokyo, JapanPurpose: To prospectively investigate adverse reactions to bimatoprost in Japanese...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Inoue K, Shiokawa M, Sugahara M, Higa R, Wakakura M, Tomita G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/1dc51342b2524e01aeb6694edda7e1ac
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
por: Inoue K, et al.
Publicado: (2014)

Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment
por: Gerrett Brief, et al.
Publicado: (2010)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
por: Pillunat LE, et al.
Publicado: (2016)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
por: Lee D, et al.
Publicado: (2017)

Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
por: Laube T, et al.
Publicado: (2012)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers JS, et al.
Publicado: (2014)

An observational study of bimatoprost 0.01% in treatment-na&iuml;ve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial
por: Nixon DR, et al.
Publicado: (2012)

Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
por: Inoue K, et al.
Publicado: (2012)

Plateau iris in Japanese patients with primary angle closure and primary angle closure glaucoma
por: Mizoguchi T, et al.
Publicado: (2015)

Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides
por: Scott D Smid
Publicado: (2009)

A combined analysis of five observational studies evaluating the efficacy and tolerability of bimatoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension
por: Pfennigsdorf S, et al.
Publicado: (2013)

Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from &szlig;-blockers and prostaglandin analogs
por: Inoue K, et al.
Publicado: (2012)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura T, et al.
Publicado: (2012)

Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
por: Tsumura T, et al.
Publicado: (2013)

Topical Medication Therapy for Glaucoma and Ocular Hypertension
por: Tao Wang, et al.
Publicado: (2021)

Safety and efficacy of a fixed versus unfixed brinzolamide/timolol combination in Japanese patients with open-angle glaucoma or ocular hypertension
por: Nagayama M, et al.
Publicado: (2014)

Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
por: Inoue K, et al.
Publicado: (2012)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
por: Tsumura T, et al.
Publicado: (2013)

A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
por: Stevens A, et al.
Publicado: (2016)

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension
por: Yoshikawa K, et al.
Publicado: (2014)

Phase III safety and efficacy study of long-term brinzolamide/timolol fixed combination in Japanese patients with open-angle glaucoma or ocular hypertension
por: Nakajima M, et al.
Publicado: (2013)

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension [Erratum]
por: Yoshikawa K, et al.
Publicado: (2014)

Development of ocular hypertension and persistent glaucoma after intravitreal injection of triamcinolone
por: M Selim Kocabora, et al.
Publicado: (2008)

Correlation between ocular perfusion pressure and ocular pulse amplitude in glaucoma, ocular hypertension, and normal eyes
por: Figueiredo BP, et al.
Publicado: (2013)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee A, et al.
Publicado: (2013)

Managing adverse effects of glaucoma medications
por: Inoue K
Publicado: (2014)

Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
por: Pacella F, et al.
Publicado: (2012)

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension
por: Lanzl I, et al.
Publicado: (2013)

Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
por: Anna Galanopoulos, et al.
Publicado: (2008)

Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue
por: Nakano T, et al.
Publicado: (2016)

Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review
por: Takagi Y, et al.
Publicado: (2018)

Baerveldt implant for secondary glaucoma due to iris melanoma
por: Annelie N Tan, et al.
Publicado: (2010)

Periocular xanthogranuloma: A forgotten entity?
por: Charalampos Papagoras, et al.
Publicado: (2010)

Relationships between central corneal thickness and optic disc topography in eyes with glaucoma, suspicion of glaucoma, or ocular hypertension
por: Pinakin Gunvant, et al.
Publicado: (2008)

Incidence and Risk Factors of Ocular Hypertension/Glaucoma After Descemet Stripping Automated Endothelial Keratoplasty
por: Elalfy M, et al.
Publicado: (2021)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
por: Gregory Katz, et al.
Publicado: (2010)

Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension
por: Sophia K Mirza, et al.
Publicado: (2010)

Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
por: Ermiş&nbsp;SS
Publicado: (2012)

Blood pressure, ocular perfusion pressure and open-angle glaucoma in patients with systemic hypertension
por: Cantor E, et al.
Publicado: (2018)

Acquired color vision and visual field defects in patients with ocular hypertension and early glaucoma
por: Dimitris Papaconstantinou, et al.
Publicado: (2009)